US2022313725A1PendingUtilityA1

Implantable Medical Device for the Delivery of a Nucleic Acid

52
Assignee: CELANESE EVA PERFORMANCE POLYMERS LLCPriority: Mar 30, 2021Filed: Mar 28, 2022Published: Oct 6, 2022
Est. expiryMar 30, 2041(~14.7 yrs left)· nominal 20-yr term from priority
Inventors:Jeffrey C. HaleyVijay GyananiBrian D. WilsonHarsh PatelNarsi Devanathan
B33Y 80/00B29L 2031/702B29C 48/02A61K 31/7105A61K 9/0024A61K 9/146B29L 2031/7532B29C 48/05B29C 48/022B29C 48/505B29L 2031/753A61K 47/32A61K 39/3955B29K 2105/0035
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An implantable medical device is provided. The device comprises a drug release layer, wherein the drug release layer comprises a naked nucleic acid dispersed within a polymer matrix. The polymer matrix includes an ethylene vinyl acetate copolymer and has a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15 and a melt flow index of from about 0.2 to about 100 gram per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An implantable medical device comprising a drug release layer, wherein the drug release layer comprises a naked nucleic acid dispersed within a polymer matrix, wherein the polymer matrix includes an ethylene vinyl acetate copolymer and has a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15 and a melt flow index of from about 0.2 to about 100 gram per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms. 
     
     
         2 . The implantable medical device of  claim 1 , wherein the weight ratio of the polymer matrix to the nucleic acid is from about 1 to about 10. 
     
     
         3 . The implantable medical device of  claim 1 , wherein the ethylene vinyl acetate copolymer has a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15. 
     
     
         4 . The implantable medical device of  claim 1 , wherein ethylene vinyl acetate copolymers constitute the entire polymer content of the polymer matrix. 
     
     
         5 . The implantable medical device of  claim 1 , wherein the polymer matrix further includes a plasticizer. 
     
     
         6 . The implantable medical device of  claim 1 , wherein the polymer matrix further includes a hydrophobic polymer. 
     
     
         7 . The implantable medical device of  claim 6 , wherein the polymer matrix includes a first ethylene vinyl acetate copolymer and a second ethylene vinyl acetate copolymer. 
     
     
         8 . The implantable medical device of  claim 1 , wherein the vinyl acetate content of the copolymer is from about 10 wt. % to about 60 wt. %. 
     
     
         9 . The implantable medical device of  claim 1 , wherein the ethylene vinyl acetate polymer has a melt flow index of from about 0.2 to about 100 grams per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms. 
     
     
         10 . The implantable medical device of  claim 1 , wherein the nucleic acid includes a ribonucleic acid. 
     
     
         11 . The implantable medical device of  claim 10 , wherein the ribonucleic acid includes mRNA. 
     
     
         12 . The implantable medical device of  claim 11 , wherein the mRNA includes a therapeutic mRNA containing at least one ribonucleic acid polynucleotide having an open reading frame encoding at least one antigenic polypeptide. 
     
     
         13 . The implantable medical device of  claim 1 , wherein the device has a generally circular cross-sectional shape. 
     
     
         14 . The implantable medical device of  claim 13 , wherein the device has a diameter of from about 0.5 to about 50 millimeters. 
     
     
         15 . The implantable medical device of  claim 1 , wherein the device is in the form of a cylinder. 
     
     
         16 . The implantable medical device of  claim 1 , wherein the device is in the form of a disc. 
     
     
         17 . The implantable medical device of  claim 1 , wherein the drug release layer further includes a ribonucleic acid degradation inhibitor. 
     
     
         18 . The implantable medical device of  claim 17 , wherein the ribonucleic acid inhibitor includes an anti-ribonuclease antibody. 
     
     
         19 . The implantable medical device of  claim 17 , wherein the ribonucleic acid inhibitor includes a chelating agent. 
     
     
         20 . The implantable medical device of  claim 1 , wherein the drug release layer further includes a cell permeability enhancer. 
     
     
         21 . The implantable medical device of  claim 1 , wherein the drug release layer further includes a hydrophilic compound. 
     
     
         22 . The implantable medical device of  claim 21 , wherein the hydrophilic compound includes a hydrophilic polymer. 
     
     
         23 . The implantable medical device of  claim 22 , wherein the hydrophilic polymer includes a sodium, potassium or calcium alginate, carboxymethylcellulose, agar, gelatin, polyvinyl alcohol, polyalkylene glycol, collagen, pectin, chitin, chitosan, poly-1-caprolactone, polyvinylpyrrolidone, poly(vinylpyrrolidone-co-vinyl acetate), polysaccharide, hydrophilic polyurethane, polyhydroxyacrylate, dextran, xanthan, hydroxypropyl cellulose, methylcellulose, protein, ethylene vinyl alcohol copolymer, water-soluble polysilane, water-soluble silicone, water-soluble polyurethane, or a combination thereof. 
     
     
         24 . The implantable medical device of  claim 1 , wherein the nucleic acid constitutes from about 1 wt. % to about 60 wt. % of the drug release layer and the polymer matrix constitutes from about 40 wt. % to about 99 wt. % of the drug release layer. 
     
     
         25 . The implantable medical device of  claim 1 , further comprising a membrane layer positioned adjacent to an outer surface of the drug release layer. 
     
     
         26 . The implantable medical device of  claim 25 , wherein the membrane layer is free of a nucleic acid. 
     
     
         27 . The implantable medical device of  claim 25 , wherein the membrane layer comprises a membrane polymer matrix comprising a hydrophobic polymer. 
     
     
         28 . The implantable medical device of  claim 27 , wherein the hydrophobic polymer includes an ethylene vinyl acetate copolymer. 
     
     
         29 . The implantable medical device of  claim 27 , wherein the membrane polymer matrix is formed entirely from hydrophobic polymers. 
     
     
         30 . The implantable medical device of  claim 27 , wherein the membrane polymer matrix also contains a hydrophilic compound. 
     
     
         31 . A method for forming the implantable medical device of  claim 1 , the method comprising melt blending the naked nucleic acid and the polymer matrix within an extruder. 
     
     
         32 . The method of  claim 31 , wherein melt blending occurs at a temperature of from about 30° C. to about 100° C. 
     
     
         33 . The method of  claim 31 , wherein the extruder includes a rotatable screw having a length and diameter, wherein the ratio of the length to the diameter is from about 10 to about 50. 
     
     
         34 . A method for prohibiting and/or treating a condition, disease, and/or cosmetic state of a patient, the method comprising subcutaneously implanting the device of  claim 1  in the patient.

Join the waitlist — get patent alerts

Track US2022313725A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.